Listing 1 - 6 of 6 |
Sort by
|
Choose an application
The objective of this study was to examine the effect of abrupt weaning (inclusive of social group disruption and maternal separation) on the physiological mediators of stress and measures of immune function. Thirty-six male and 36 female calves (Limousin and Charolais crosses), habituated to handling, were blocked by sex, weight, and breed of dam and randomly assigned, within block, to either a control or abruptly weaned group. Animals were separated into the respective treatment groups at 0 h. Calves were bled at -168, 6 (males only), 24, 48, and 168 h after weaning, and the behavioral reaction of calves to handling was scored. Cortisol, catecholamine (not sampled at -168 h), acute-phase protein concentrations, and in vitro interferon-gamma production and neutrophil:lymphocyte ratio were measured. The effects of weaning, calf sex, time, and their respective. interactions were described. Disruption of the established social group at 0 h increased (P < 0.001) the plasma cortisol concentration and neutrophil:lymphocyte ratio and decreased the leukocyte concentration (P < 0.001) and the in vitro interferon-gamma response to the mitogen concanavalin-A (P < 0.001) and keyhole limpet hemocyanin (P < 0.001) for weaned and control animals compared with -168 E There was no effect of weaning or sex on the behavioral reaction of calves to handling. Plasma cortisol and adrenaline concentrations were not affected by weaning or sex. Plasma noradrenaline concentration was influenced by weaning x sex (P < 0.05) and time x sex (P < 0.05). The, response increased for male calves with weaning and increased with each sampling time after weaning. For heifers,,the response was not affected by weaning and plasma concentrations decreased at 168 h after weaning. There was no effect of weaning or sex on leukocyte concentration. The neutrophil:lymphocyte ratio increased after weaning (P < 0.01) and was affected by sex (P < 0.05). Weaning decreased (P < 0.05) the in vitro interferon-gamma
Animal. --- Animals. --- Breed. --- Bull calves. --- Calves,catecholamines,cortisol,immunity,stress,weaning. --- Calves. --- Catecholamine. --- Catecholamines. --- Cattle. --- Control. --- Cortisol. --- Cows. --- Dexamethasone. --- Disruption. --- Female. --- Function. --- Group. --- Handling. --- Haptoglobin response. --- Immune-responses. --- Immune. --- Interaction. --- Interactions. --- Keyhole limpet hemocyanin. --- Male. --- Males. --- Maternal separation. --- Maternal. --- Neutrophil:lymphocyte ratio. --- Noradrenaline. --- Physiological. --- Pituitary-adrenal axis. --- Plasma-cortisol. --- Plasma. --- Production. --- Protein. --- Response. --- Separation. --- Sex. --- Sexes. --- Social. --- Space allowance. --- Stress-response. --- Stress. --- Time. --- Treatment. --- Weaning. --- Weight.
Choose an application
There are various malignant tumors in the head and neck area, including oral cavity, pharynx, sinonasal cavity, and salivary glands. Squamous cell carcinoma is the most common cancer among head and neck cancers. In salivary glands, there are many types of malignancies that can develop, such as malignant lymphoma, adenoid cystic carcinoma, adenocarcinoma, and mesenchymal tumors. In a clinical setting, imaging, such as computed tomography (CT) and magnetic resonance imaging (MRI), is very important in terms of the prediction of the histological type and the evaluation of the extent of invasion of adjacent structures. In basic research, there are few animal models in head and neck malignancies. In this Special Issue, we broadly discuss the basic and clinical research in head and neck malignancies.
Medicine --- BDNF --- Brain-Derived Neurotrophic Factor --- navigation --- spatial processing --- trauma --- trauma processing --- Post-Traumatic Stress Disorder --- PSTD --- allocentric --- hippocampus --- sinonasal tract --- malignant tumor --- CT --- MRI --- neuropsychiatric presentation of encephalitis --- paraneoplastic encephalitis --- autoimmune encephalitis --- infectious encephalitis --- diffuse large B-cell lymphoma --- canaloplasty --- non-perforating surgical procedures --- corticosteroid-induced glaucoma --- Schlemm’s canal --- neck mass --- diffusion-weighted MRI --- apparent diffusion coefficient --- procalcitonin --- bacterial meningitis --- viral meningitis --- antibiotic therapy --- biomarker --- differential diagnosis --- human papillomavirus --- human cancer --- head and neck --- reduction therapy --- head and neck squamous cell carcinoma (HNSCC) --- neutrophil-to-lymphocyte ratio (NLR) --- myeloid-derived suppressor cells (MDSC) --- aldehyde dehydrogenase 1 (ALDH1) --- prognosis --- prodigiosin --- doxorubicin --- priming --- influx --- autophagy --- cervical --- cellulitis --- abscess --- deep neck infection --- diabetes mellitus --- MAP1LC3B --- SQSTM1 --- subsites --- tumorigenesis --- oral cancer --- Nox4 --- oral tongue cancer --- squamous cell carcinoma --- surgery --- head and neck squamous cell carcinoma --- HPV --- 11q13 --- gene amplification --- immunohistochemistry --- head and neck cancer --- radiotherapy --- neutrophil/lymphocyte ratio --- survival --- ZFAND4 --- ANUBL1 --- oral squamous cell carcinoma --- nucleotide excision repair --- genetic polymorphism --- concurrent chemoradiotherapy --- HNSCC --- MIF --- 4-IPP --- metabolism --- annexin A9 --- annexin A10 --- differentiation grade --- NGS --- BDNF --- Brain-Derived Neurotrophic Factor --- navigation --- spatial processing --- trauma --- trauma processing --- Post-Traumatic Stress Disorder --- PSTD --- allocentric --- hippocampus --- sinonasal tract --- malignant tumor --- CT --- MRI --- neuropsychiatric presentation of encephalitis --- paraneoplastic encephalitis --- autoimmune encephalitis --- infectious encephalitis --- diffuse large B-cell lymphoma --- canaloplasty --- non-perforating surgical procedures --- corticosteroid-induced glaucoma --- Schlemm’s canal --- neck mass --- diffusion-weighted MRI --- apparent diffusion coefficient --- procalcitonin --- bacterial meningitis --- viral meningitis --- antibiotic therapy --- biomarker --- differential diagnosis --- human papillomavirus --- human cancer --- head and neck --- reduction therapy --- head and neck squamous cell carcinoma (HNSCC) --- neutrophil-to-lymphocyte ratio (NLR) --- myeloid-derived suppressor cells (MDSC) --- aldehyde dehydrogenase 1 (ALDH1) --- prognosis --- prodigiosin --- doxorubicin --- priming --- influx --- autophagy --- cervical --- cellulitis --- abscess --- deep neck infection --- diabetes mellitus --- MAP1LC3B --- SQSTM1 --- subsites --- tumorigenesis --- oral cancer --- Nox4 --- oral tongue cancer --- squamous cell carcinoma --- surgery --- head and neck squamous cell carcinoma --- HPV --- 11q13 --- gene amplification --- immunohistochemistry --- head and neck cancer --- radiotherapy --- neutrophil/lymphocyte ratio --- survival --- ZFAND4 --- ANUBL1 --- oral squamous cell carcinoma --- nucleotide excision repair --- genetic polymorphism --- concurrent chemoradiotherapy --- HNSCC --- MIF --- 4-IPP --- metabolism --- annexin A9 --- annexin A10 --- differentiation grade --- NGS
Choose an application
Dear colleagues, This Special Issue, “Endothelial Dysfunction: From Pathophysiology to Novel Therapeutic Approaches”, focuses on the pathophysiology of endothelial dysfunction, new biomarkers for endothelial dysfunction related to cardiovascular disorders or tumors, and novel therapeutic approaches for endothelial dysfunctions. Vascular endothelium is an active tissue and plays a crucial role in the maintenance of vascular homeostasis. Chronic exposure to risk factors, such as hypertension, high cholesterolemia, or oxidative stress, induces endothelial dysfunctions and results in a loss of endothelial integrity, smooth muscle cell proliferation, and macrophage recruitment. The pathophysiology of endothelial dysfunction (ED) is complex and multi-factorial factors are involved, such as oxidative stress or chronic inflammation. The primary prevention of cardiovascular risk factors and endothelial dysfunctions, as well as the early detection of or molecular imaging techniques for endothelial dysfunction, helps to prevent the development of cardiovascular disorders. Novel therapeutic approaches or drug delivery systems for endothelial dysfunctions have had promising beneficial effects in preclinical or clinical levels by affecting the progression of atherosclerotic changes, tumor angiogenesis, and host–immune reactions near tumor environments.
Technology: general issues --- Biotechnology --- endothelial cells --- oxidative stress --- inflammageing --- endothelial dysfunction --- aldehyde dehydrogenase-2 --- cardiovascular disease --- neurovascular disease --- vascular inflammation --- APE1/Ref-1 --- cardiovascular diseases --- subcellular localization --- serological biomarkers --- atherosclerosis --- aerobic exercise --- PCSK9 --- LOX-1 --- insulin resistance --- macrophage polarity --- serum γ-glutamyltransferase --- essential hypertension --- cardiovascular risk factors --- angiogenesis --- nargenicin A1 --- compound 9 --- VEGF --- VEGFR2 --- HIF-1α --- electronegative low-density lipoprotein --- LDL(-) --- L5 LDL --- oxidized LDL --- oxLDL --- ADMA --- arginine --- arginine paradox --- BH4 --- blood pressure --- COVID-19 --- dietary supplements --- endothelium --- eNOS uncoupling --- heart failure --- hypertension --- L-arginine --- myocardial infarction --- NADPH --- nitric oxide --- peripheral artery disease --- ApoE knockout mouse --- atorvastatin --- VCAM-1 --- galectin-3 --- neutrophil/lymphocyte ratio --- electronegative LDL --- LDL(−) --- lectin-like oxLDL receptor-1 --- dyslipidemia --- chronic venous insufficiency --- prolyl oligopeptidase (POP) --- inflammation --- endothelial disfunction --- lung disease --- endothelial to mesenchymal transition --- pulmonary hypertension --- pulmonary fibrosis --- metformin --- diabetes --- CV risk --- hyperglycemia --- glycated lipoproteins --- glycated LDL --- glycated HDL --- endothelial cell dysfunction --- molecular mechanisms --- epigenetic factors --- therapeutic approaches --- vasoactive factors --- EndoMT --- TGF-β --- epigenetics --- endothelial cell --- glycolysis --- metabolism --- pathological angiogenesis --- tumor microenvironment --- MRI (magnetic resonance imaging) --- high-fat diets --- plaque burden --- low-level laser therapy --- phototherapy --- vascular disease --- healing --- ischemia --- vascular calcification --- chronic kidney disease --- CKD --- uremic toxins --- hyperphosphatemia --- vascular smooth muscle cells --- VSMCs --- macrophages --- endothelial cells --- oxidative stress --- inflammageing --- endothelial dysfunction --- aldehyde dehydrogenase-2 --- cardiovascular disease --- neurovascular disease --- vascular inflammation --- APE1/Ref-1 --- cardiovascular diseases --- subcellular localization --- serological biomarkers --- atherosclerosis --- aerobic exercise --- PCSK9 --- LOX-1 --- insulin resistance --- macrophage polarity --- serum γ-glutamyltransferase --- essential hypertension --- cardiovascular risk factors --- angiogenesis --- nargenicin A1 --- compound 9 --- VEGF --- VEGFR2 --- HIF-1α --- electronegative low-density lipoprotein --- LDL(-) --- L5 LDL --- oxidized LDL --- oxLDL --- ADMA --- arginine --- arginine paradox --- BH4 --- blood pressure --- COVID-19 --- dietary supplements --- endothelium --- eNOS uncoupling --- heart failure --- hypertension --- L-arginine --- myocardial infarction --- NADPH --- nitric oxide --- peripheral artery disease --- ApoE knockout mouse --- atorvastatin --- VCAM-1 --- galectin-3 --- neutrophil/lymphocyte ratio --- electronegative LDL --- LDL(−) --- lectin-like oxLDL receptor-1 --- dyslipidemia --- chronic venous insufficiency --- prolyl oligopeptidase (POP) --- inflammation --- endothelial disfunction --- lung disease --- endothelial to mesenchymal transition --- pulmonary hypertension --- pulmonary fibrosis --- metformin --- diabetes --- CV risk --- hyperglycemia --- glycated lipoproteins --- glycated LDL --- glycated HDL --- endothelial cell dysfunction --- molecular mechanisms --- epigenetic factors --- therapeutic approaches --- vasoactive factors --- EndoMT --- TGF-β --- epigenetics --- endothelial cell --- glycolysis --- metabolism --- pathological angiogenesis --- tumor microenvironment --- MRI (magnetic resonance imaging) --- high-fat diets --- plaque burden --- low-level laser therapy --- phototherapy --- vascular disease --- healing --- ischemia --- vascular calcification --- chronic kidney disease --- CKD --- uremic toxins --- hyperphosphatemia --- vascular smooth muscle cells --- VSMCs --- macrophages
Choose an application
Dear colleagues, This Special Issue, “Endothelial Dysfunction: From Pathophysiology to Novel Therapeutic Approaches”, focuses on the pathophysiology of endothelial dysfunction, new biomarkers for endothelial dysfunction related to cardiovascular disorders or tumors, and novel therapeutic approaches for endothelial dysfunctions. Vascular endothelium is an active tissue and plays a crucial role in the maintenance of vascular homeostasis. Chronic exposure to risk factors, such as hypertension, high cholesterolemia, or oxidative stress, induces endothelial dysfunctions and results in a loss of endothelial integrity, smooth muscle cell proliferation, and macrophage recruitment. The pathophysiology of endothelial dysfunction (ED) is complex and multi-factorial factors are involved, such as oxidative stress or chronic inflammation. The primary prevention of cardiovascular risk factors and endothelial dysfunctions, as well as the early detection of or molecular imaging techniques for endothelial dysfunction, helps to prevent the development of cardiovascular disorders. Novel therapeutic approaches or drug delivery systems for endothelial dysfunctions have had promising beneficial effects in preclinical or clinical levels by affecting the progression of atherosclerotic changes, tumor angiogenesis, and host–immune reactions near tumor environments.
Technology: general issues --- Biotechnology --- endothelial cells --- oxidative stress --- inflammageing --- endothelial dysfunction --- aldehyde dehydrogenase-2 --- cardiovascular disease --- neurovascular disease --- vascular inflammation --- APE1/Ref-1 --- cardiovascular diseases --- subcellular localization --- serological biomarkers --- atherosclerosis --- aerobic exercise --- PCSK9 --- LOX-1 --- insulin resistance --- macrophage polarity --- serum γ-glutamyltransferase --- essential hypertension --- cardiovascular risk factors --- angiogenesis --- nargenicin A1 --- compound 9 --- VEGF --- VEGFR2 --- HIF-1α --- electronegative low-density lipoprotein --- LDL(–) --- L5 LDL --- oxidized LDL --- oxLDL --- ADMA --- arginine --- arginine paradox --- BH4 --- blood pressure --- COVID-19 --- dietary supplements --- endothelium --- eNOS uncoupling --- heart failure --- hypertension --- L-arginine --- myocardial infarction --- NADPH --- nitric oxide --- peripheral artery disease --- ApoE knockout mouse --- atorvastatin --- VCAM-1 --- galectin-3 --- neutrophil/lymphocyte ratio --- electronegative LDL --- LDL(−) --- lectin-like oxLDL receptor-1 --- dyslipidemia --- chronic venous insufficiency --- prolyl oligopeptidase (POP) --- inflammation --- endothelial disfunction --- lung disease --- endothelial to mesenchymal transition --- pulmonary hypertension --- pulmonary fibrosis --- metformin --- diabetes --- CV risk --- hyperglycemia --- glycated lipoproteins --- glycated LDL --- glycated HDL --- endothelial cell dysfunction --- molecular mechanisms --- epigenetic factors --- therapeutic approaches --- vasoactive factors --- EndoMT --- TGF-β --- epigenetics --- endothelial cell --- glycolysis --- metabolism --- pathological angiogenesis --- tumor microenvironment --- MRI (magnetic resonance imaging) --- high-fat diets --- plaque burden --- low-level laser therapy --- phototherapy --- vascular disease --- healing --- ischemia --- vascular calcification --- chronic kidney disease --- CKD --- uremic toxins --- hyperphosphatemia --- vascular smooth muscle cells --- VSMCs --- macrophages --- n/a --- LDL(-)
Choose an application
There are various malignant tumors in the head and neck area, including oral cavity, pharynx, sinonasal cavity, and salivary glands. Squamous cell carcinoma is the most common cancer among head and neck cancers. In salivary glands, there are many types of malignancies that can develop, such as malignant lymphoma, adenoid cystic carcinoma, adenocarcinoma, and mesenchymal tumors. In a clinical setting, imaging, such as computed tomography (CT) and magnetic resonance imaging (MRI), is very important in terms of the prediction of the histological type and the evaluation of the extent of invasion of adjacent structures. In basic research, there are few animal models in head and neck malignancies. In this Special Issue, we broadly discuss the basic and clinical research in head and neck malignancies.
BDNF --- Brain-Derived Neurotrophic Factor --- navigation --- spatial processing --- trauma --- trauma processing --- Post-Traumatic Stress Disorder --- PSTD --- allocentric --- hippocampus --- sinonasal tract --- malignant tumor --- CT --- MRI --- neuropsychiatric presentation of encephalitis --- paraneoplastic encephalitis --- autoimmune encephalitis --- infectious encephalitis --- diffuse large B-cell lymphoma --- canaloplasty --- non-perforating surgical procedures --- corticosteroid-induced glaucoma --- Schlemm’s canal --- neck mass --- diffusion-weighted MRI --- apparent diffusion coefficient --- procalcitonin --- bacterial meningitis --- viral meningitis --- antibiotic therapy --- biomarker --- differential diagnosis --- human papillomavirus --- human cancer --- head and neck --- reduction therapy --- head and neck squamous cell carcinoma (HNSCC) --- neutrophil-to-lymphocyte ratio (NLR) --- myeloid-derived suppressor cells (MDSC) --- aldehyde dehydrogenase 1 (ALDH1) --- prognosis --- prodigiosin --- doxorubicin --- priming --- influx --- autophagy --- cervical --- cellulitis --- abscess --- deep neck infection --- diabetes mellitus --- MAP1LC3B --- SQSTM1 --- subsites --- tumorigenesis --- oral cancer --- Nox4 --- oral tongue cancer --- squamous cell carcinoma --- surgery --- head and neck squamous cell carcinoma --- HPV --- 11q13 --- gene amplification --- immunohistochemistry --- head and neck cancer --- radiotherapy --- neutrophil/lymphocyte ratio --- survival --- ZFAND4 --- ANUBL1 --- oral squamous cell carcinoma --- nucleotide excision repair --- genetic polymorphism --- concurrent chemoradiotherapy --- HNSCC --- MIF --- 4-IPP --- metabolism --- annexin A9 --- annexin A10 --- differentiation grade --- NGS
Choose an application
Dear colleagues, This Special Issue, “Endothelial Dysfunction: From Pathophysiology to Novel Therapeutic Approaches”, focuses on the pathophysiology of endothelial dysfunction, new biomarkers for endothelial dysfunction related to cardiovascular disorders or tumors, and novel therapeutic approaches for endothelial dysfunctions. Vascular endothelium is an active tissue and plays a crucial role in the maintenance of vascular homeostasis. Chronic exposure to risk factors, such as hypertension, high cholesterolemia, or oxidative stress, induces endothelial dysfunctions and results in a loss of endothelial integrity, smooth muscle cell proliferation, and macrophage recruitment. The pathophysiology of endothelial dysfunction (ED) is complex and multi-factorial factors are involved, such as oxidative stress or chronic inflammation. The primary prevention of cardiovascular risk factors and endothelial dysfunctions, as well as the early detection of or molecular imaging techniques for endothelial dysfunction, helps to prevent the development of cardiovascular disorders. Novel therapeutic approaches or drug delivery systems for endothelial dysfunctions have had promising beneficial effects in preclinical or clinical levels by affecting the progression of atherosclerotic changes, tumor angiogenesis, and host–immune reactions near tumor environments.
endothelial cells --- oxidative stress --- inflammageing --- endothelial dysfunction --- aldehyde dehydrogenase-2 --- cardiovascular disease --- neurovascular disease --- vascular inflammation --- APE1/Ref-1 --- cardiovascular diseases --- subcellular localization --- serological biomarkers --- atherosclerosis --- aerobic exercise --- PCSK9 --- LOX-1 --- insulin resistance --- macrophage polarity --- serum γ-glutamyltransferase --- essential hypertension --- cardiovascular risk factors --- angiogenesis --- nargenicin A1 --- compound 9 --- VEGF --- VEGFR2 --- HIF-1α --- electronegative low-density lipoprotein --- LDL(–) --- L5 LDL --- oxidized LDL --- oxLDL --- ADMA --- arginine --- arginine paradox --- BH4 --- blood pressure --- COVID-19 --- dietary supplements --- endothelium --- eNOS uncoupling --- heart failure --- hypertension --- L-arginine --- myocardial infarction --- NADPH --- nitric oxide --- peripheral artery disease --- ApoE knockout mouse --- atorvastatin --- VCAM-1 --- galectin-3 --- neutrophil/lymphocyte ratio --- electronegative LDL --- LDL(−) --- lectin-like oxLDL receptor-1 --- dyslipidemia --- chronic venous insufficiency --- prolyl oligopeptidase (POP) --- inflammation --- endothelial disfunction --- lung disease --- endothelial to mesenchymal transition --- pulmonary hypertension --- pulmonary fibrosis --- metformin --- diabetes --- CV risk --- hyperglycemia --- glycated lipoproteins --- glycated LDL --- glycated HDL --- endothelial cell dysfunction --- molecular mechanisms --- epigenetic factors --- therapeutic approaches --- vasoactive factors --- EndoMT --- TGF-β --- epigenetics --- endothelial cell --- glycolysis --- metabolism --- pathological angiogenesis --- tumor microenvironment --- MRI (magnetic resonance imaging) --- high-fat diets --- plaque burden --- low-level laser therapy --- phototherapy --- vascular disease --- healing --- ischemia --- vascular calcification --- chronic kidney disease --- CKD --- uremic toxins --- hyperphosphatemia --- vascular smooth muscle cells --- VSMCs --- macrophages --- n/a --- LDL(-)
Listing 1 - 6 of 6 |
Sort by
|